Fig. 4From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatmentPET imaging and biodistribution of 89Zr-DFO-YS5 in PC3 subcu-CDX model. A PET/CT images of PC3 tumors at 24, 72 and 120Â h post-administration of 89Zr-DFO-YS5. B Tumor/non-tumor ratio derived from PET images at 24, 72 and 120Â h post-administration of 89Zr-DFO-YS5. C Biodistribution of 89Zr-DFO-YS5 at 120Â h post-administrationBack to article page